April 22nd 2024
Rhonda Henschel, MBA, discussed the challenges and considerations for community oncology practices looking to implement cellular therapy programs.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
CAR T Cell Agents Show Variance in Different Lymphoma Subtypes
July 8th 2020Chimeric antigen receptor T-cell therapy when administered to patients with non-follicular low-grade lymphoma may experience different efficacy outcomes than patients with aggressive B-cell lymphomas, according to a single-institution retrospective data.
Read More
Researcher Evaluates Next Steps for Incorporating CAR T-Cell Therapy into Solid Tumor Space
June 23rd 2020In an interview with Targeted Oncology, Prasad S. Adusumilli, MD, FACS, discussed how CAR T-cell therapy could play a role in the treatment of solid tumors. He highlighted the current research and next steps planned to move this cellular therapy into the solid tumor treatment landscape.
Read More
Evaluating the Potential for CAR T Cells as Treatment of Solid Tumors
June 15th 2020Prasad S. Adusumilli, MD, FACS, discusses the potential role of chimeric antigen receptor T-cell therapy as treatment of solid tumors now that they have demonstrated safety and efficacy in some Hematologic Malignancies.
Watch
CAR T Cells May Be Safely Administered in Outpatient Setting for Patients With B-Cell Lymphomas
June 10th 2020In an interview with Targeted Oncology, David G. Maloney, MD, PhD, discussed findings from administration of chimeric antigen receptor T-cell therapy in the outpatient setting for patients with B-cell lymphomas.
Read More
Optimized Tandem CAR T-Cell Therapy Targeted CD19/CD20 Appears Feasible in B-NHL
June 2nd 2020Although many of the patients in the study had heavy tumor burden, were in poor physical condition, or had highly aggressive characteristics, they were still able to achieve a satisfactory overall response rate and complete response rate with the tandem CD19/CD20 CAR-engineered T-cell therapy.
Read More
Integrating EMR Into the Clinical Management of CAR T-Cell Therapy Improves Patient Care
May 14th 2020In an interview with Targeted Oncology, Andrea Price, APN, discussed the importance of integrating the electronic medical record team into the clinical care team for the treatment of patients with cancer receiving CAR T-cell therapy.
Read More
FDA Halts Review of BLA for Ide-cel in R/R Multiple Myeloma Pending Additional Data
May 13th 2020The review of the Biologics License Application for idecabtagene vicleucel has been put on hold. The FDA issued a Refusal to File letter due to the need for additional data from the developer of the drug.
Read More
Protocol Management, Off-the-Shelf Therapies Help Bring CAR T Into More Settings
May 12th 2020Relevant professional meetings and oncology publications exploded with research and news about chimeric antigen receptor T cells, and this cellular therapy strategy is now being explored across hematologic and solid malignancies.
Read More
Higher CAR T-Cell Dosage Improves Efficacy Without Toxicity in Relapsed or Refractory CLL
May 10th 2020Patients with relapsed or refractory chronic lymphocytic leukemia who received a higher dose of CAR T cells, achieved complete responses, regardless of cell dose, which was highly correlated with long-term survival.
Read More
Community Oncologists Critical to Success of CAR T-cell Therapy in R/R Large B-Cell Lymphoma
April 28th 2020Few options exist for patients with relapsed or refractory large B-cell lymphomas who have already undergone 2 rounds of systemic therapy. New research shows axicabtagene ciloleucel might be a strong option, but community oncologists must play a role in patient identification and post-treatment follow-up.
Read More
Evaluating the Feasibility of Liso-cel Administration in the Outpatient Setting
April 22nd 2020Carlos R. Bachier, MD, discusses how an analysis of 3 clinical trials evaluating the efficacy of lisocabtagene maraleucel demonstrated the feasibility of outpatient administration of chimeric antigen receptor T-cell therapy.
Watch
FDA Grants RMAT Designation to Tisagenlecleucel in R/R Follicular Lymphoma
April 22nd 2020“This designation supports the advancement of Kymriah, which could potentially address an unmet need in certain patients with follicular lymphoma, as we strive to reimagine medicine at Novartis. These patients are often faced with the burden of several years of various treatments as their disease continues to progress.”
Read More
ZUMA-2 Update: KTE-X19 Induced Durable Remission in R/R Mantle Cell Lymphoma
April 3rd 2020Durable remissions were elicited with KTE-X19 in a majority of patients with relapsed or refractory mantle cell lymphoma, according to the updated results from the ZUMA-2 trial published in the New England Journal of Medicine. The treatment did, however, cause serious adverse events that were consistent with known toxicities of chimeric antigen receptor T-cell therapy.
Read More
CAR T Cells Push Forward in Solid Tumors Following Positive Results in Hematology
April 1st 2020In an interview with Targeted Oncology, Prasad S. Adusumilli, MD, FACS, discussed the expansion of chimeric antigen receptor T-cell research in the solid tumor space and the challenges researchers will need to overcome in order to make this therapy effective for patients outside of the hematologic treatment landscape.
Read More
FDA Approval Sought for Ide-cel in Relapsed/Refractory Multiple Myeloma
March 31st 2020A Biologics License Application has been submitted to the FDA for the investigational B-cell maturation antigen-directed chimeric antigen receptor T cell immunotherapy idecabtagene vicleucel as treatment of patients with multiple myeloma who have received at least 3 prior therapies.
Read More
Existing CAR T Cells Show Promise Even as Newer Agents Emerge in Multiple Myeloma
February 28th 2020In an interview with Targeted Oncology at the 2020 International Congress on Hematologic Malignancies, Noopur Raje, MD, discussed emerging CAR T-cell therapies in multiple myeloma. She also explained how CAR NK cells differ from other CAR agents.
Read More
Favorable Safety and Efficacy May Be Possible With Off-the-Shelf CAR T Cells in NHL
February 22nd 2020Use of an off-the-shelf chimeric antigen receptor T-cell product may be feasible for use in patients with relapsed/refractory B-cell malignancies for whom no other available therapies exist, according to results of a phase I trial in adult and pediatric patients that were presented at the 2020 Transplant & Cellular Therapies Meeting in Orlando, Florida.
Read More
CAR T-Cell Therapy With Liso-Cel in the Outpatient Setting Reported as Safe and Effective
February 21st 2020Outpatient treatment with lisocabtagene maraleucel had consistent efficacy and safety with that of a previously reported clinical trial involving patients who were treated at university medical centers, according to results of 3 studies reported at the 2020 Transplantation & Cellular Therapy Meetings in Orlando, Florida.
Read More